From Gizmodo: The FDA Just Made It a Lot Easier for DNA Health Tests to Hit the Market

In the past, the US Food and Drug Administration has closely scrutinized consumer DNA tests that claim to inform customers whether or not they’re are at risk for a certain health condition, and with good reason: An incorrect interpretation could lead…

Read more

From Engadget RSS Feed: The FDA just changed how it reviews genetic health risk tests

FDA Commissioner Scott Gottlieb announced new rules today regarding direct-to-consumer genetic health risk (GHR) tests and the process by which they’re approved for sale. In a statement, Gottlieb explained that these sorts of tests can provide more a…

Read more

From ExtremeTechExtremeTech: 23andMe, Michael J. Fox Foundation to Study Genetic Factors of Parkinson’s

The foundation has awarded 23andMe a $4 million grant to gather more data that will be shared with the medical community.
The post 23andMe, Michael J. Fox Foundation to Study Genetic Factors of Parkinson’s appeared first on ExtremeTech.

Read more

From Engadget RSS Feed: Color’s breast and ovarian cancer DNA test is $99 through October

During Ovarian Cancer Awareness Month (September) and Breast Cancer Awareness Month (October), genetic testing company Color is reducing the price of its new BRCA Test. The test — which looks for mutations in the BRCA1 and BRCA2 genes that ar…

Read more

From GeekWire: Scientific wellness company Arivale goes national, drops prices for genetic analysis and coaching


Arivale, the Seattle-based scientific wellness company founded by genomics pioneer Leroy “Lee” Hood, is taking its genetic analysis and personal coaching program national with lower pricing for its flagship offering and the introduction of two entry level kits, targeting weight loss and heart health. At an event Thursday night at Seattle’s Museum of History & Industry, the company introduced a streamlined “Arivale Baseline” program that costs $999, replacing its previous $3,499 year-long program. The new program offers blood and genetic analysis with three coaching calls, plus text and email communication with a coach between calls to translate the results of… Read More

Read more

From Gizmodo: 23andMe Wants to Turn Your Genetic Data into a Drug-Discovery Goldmine

Since launching a decade ago, the consumer genetic testing company 23andMe has sold people more than two million DNA tests revealing information about their health and ancestry. Mail-in spit tests, though, aren’t the company’s long-term plan for striking it rich. On Tuesday, we got a peek at what is: Turning the …

Read more…

Read more

From TechCrunch: 23andMe confirms $250 million round led by Sequoia

 Genetics testing company 23andMe has formally announced that Sequoia Capital is leading an investment round in the company. This confirms the news we broke last week.  The press release says that the final amount was $250 million and that Sequoia’s Roelof Botha will be taking a board seat. Others participating in the round include new investors Euclidean Capital, Altimeter Capital and… Read More

Read more

From TechCrunch: 23andMe’s second act sits squarely in drug research and development

 The company first began making moves early in 2015, forging a partnership with Pfizer to conduct a bit of drug research using 23andMe’s genetic data. The pact was formed in the midst of orders from the Food and Drug Administration that 23andMe cease sales of its consumer health report product, which drove a major portion of both 23andMe’s revenue and brand awareness at the… Read More

Read more

From TechCrunch: Equity podcast: Roku is going public, 23andMe raises $200M and Juicero is dead

 Hello and welcome back to Equity, TechCrunch’s venture capital-themed podcast.
This week Matthew Lynley, Katie Roof, and myself — Alex! — sat down with Micah Rosenbloom, an investor with Founder Collective to sit down and chew over the week’s news.
We managed to not talk about Uber this episode, which was a welcome respite from the last few months during which we… Read More

Read more